Matthew Biegler
Stock Analyst at Oppenheimer
(1.07)
# 3,781
Out of 4,966 analysts
79
Total ratings
30%
Success rate
-12.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $1.34 | +497.01% | 3 | Aug 14, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Outperform | $32 → $30 | $9.34 | +221.20% | 2 | Jul 31, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $2.04 | +243.14% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.13 | +696.46% | 2 | May 14, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $25 → $22 | $5.46 | +302.93% | 6 | May 14, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $15 → $12 | $10.23 | +17.30% | 5 | May 6, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $1.97 | +306.09% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $7.73 | +482.15% | 5 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $112.97 | +1.80% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $24.55 | +115.89% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $12.67 | +160.46% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.69 | +1,083.43% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.59 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $10.05 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.48 | +116.05% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $10.53 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.04 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.51 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.12 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.94 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $7.20 | +4,900.00% | 1 | Nov 30, 2022 |
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $1.34
Upside: +497.01%
Nurix Therapeutics
Jul 31, 2025
Reiterates: Outperform
Price Target: $32 → $30
Current: $9.34
Upside: +221.20%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $2.04
Upside: +243.14%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.13
Upside: +696.46%
Olema Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $25 → $22
Current: $5.46
Upside: +302.93%
ORIC Pharmaceuticals
May 6, 2025
Maintains: Outperform
Price Target: $15 → $12
Current: $10.23
Upside: +17.30%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $1.97
Upside: +306.09%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $7.73
Upside: +482.15%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $112.97
Upside: +1.80%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $24.55
Upside: +115.89%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $12.67
Upside: +160.46%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.69
Upside: +1,083.43%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.59
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $10.05
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $6.48
Upside: +116.05%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $10.53
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.04
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.51
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.12
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.94
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $7.20
Upside: +4,900.00%